臨床外科68巻8号

2013年08月発行

特集 外科医のための癌免疫療法―基礎と臨床 基礎編

WT1ペプチド癌ワクチン

著者： 杉山治夫¹

所属機関： ¹大阪大学大学院医学系研究科機能診断科学

ページ範囲：P.899 - P.906

【ポイント】

◆Wilms腫瘍遺伝子WT1は小児の腎癌であるWilms腫瘍の原因遺伝子として単離された遺伝子で，種々の遺伝子の転写を制御する転写因子をコードしており，細胞の増殖，分化に重要な働きをしている．

◆WT1遺伝子の過剰発現が白血病やほとんどすべての種類の固形癌でみられることから，WT1蛋白は汎腫瘍抗原である．

◆また，白血病（がん）幹細胞で発現することから，WT1免疫療法は，cure-oriented therapyの可能性が高い．

参考文献

1）Sugiyama H：Wilms' tumor gene WT1：its oncogenic function and clinical application. Int J Hematol 73：177-187, 2001

2）Sugiyama H：WT1（Wilms' tumor gene 1）：biology and cancer immunotherapy. Jpn J Clin Oncol 40：377-387, 2010

3）Cheever MA, Allison JP, Ferris AS, et al：The prioritization of cancer antigens：a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15：5323-5337, 2009

4）Oka Y, Tsuboi A, Taguchi T, et al：Induction of WT1（Wilms' tumor gene）-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101：13885-13890, 2004

5）Tsuboi A, Oka Y, Kyo T, et al：Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 26：1410-1413, 2011

6）Morita S, Oka Y, Tsuboi A, et al：A phase I/II trial of a WT1（Wilms' tumor gene）peptide vaccine in patients with solid malignancy：safety assessment based on the phase I data. Jpn J Clin Oncol 36：231-236, 2006

7）Izumoto S, Tsuboi A, Oka Y, et al：Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108：963-971, 2008

8）Miyatake T, Ueda Y, Morimoto A, et al：WT1 Peptide Immunotherapy for Gynecologic Malignancies Resistant to Conventional Therapies：a PhaseⅡtrial. J Cancer Res Clin Oncol 139：457-463, 2013

9）Ohno S, Kyo S, Myojo S, et al：Wilms' tumor 1（WT1）peptide immunotherapy for gynecological malignancy. Anticancer Res 29：4779-4784, 2009

10）Iiyama T, Udaka K, Takeda, S, et al：WT1（Wilms' Tumor 1）peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51：519-530, 2007

11）Kaida M, Morita-Hoshi Y, Soeda A, et al：Phase 1 trial of Wilms tumor 1（WT1）peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 34：92-99, 2011

12）Okusaka T, Ueno M, Sato T, et al：Possibility of immunotherapy for biliary tract cancer：how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer（WT-BT trial）. J Hepato Biliary Pancreat Sci 19：314-318, 2012

13）Shirakata T, Oka Y, Nishida S, et al：WT1 Peptide Therapy for a Patient with Chemotherapy-resistant Salivary Gland Cancer. Anticancer Res 32：1081-1086, 2012

14）Ohta H, Hashii Y, Yoneda A, et al：WT1（Wilms' tumor 1）peptide immunotherapy for childhood rhabdomyosarcoma. Pediatric Hematology and Oncology 26：74-83, 2009

15）Hashii Y, Sato E, Ohta H, et al：WT1 peptide immunotherapy for cancer in children and young adults. Pediat Blood Cancer 55：352-355, 2010

16）Hashii Y, Sato-Miyashita E, Matsumura R, et al：WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse：successful maintenance of durable remission. Leukemia 26：530-532, 2012

17）Nishioka M, Tanemura A, Nishida S, et al：Vaccination with WT-1（Wilms' Tumor gene-1）peptide and BCG-CWS in melanoma. Eur J Dermatol 22：258-259, 2012

18）Ohno S, Okuyama R, Aruga A, et al：Phase I Trial of Wilms' Tumor 1（WT1）Peptide Vaccine with GM-CSF or CpG in Patients with Solid Malignancy. Anticancer Res 32：2263-2269, 2012

19）Dohi S, Ohno S, Ohno Y, et al：WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year：a case report. Anticancer Res 31：2441-2445, 2011